Literature DB >> 21282055

Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3.

Lalgudi S Harikrishnan1, Muthoni G Kamau, Honghe Wan, Jennifer A Inghrim, Kurt Zimmermann, Xiaopeng Sang, Harold A Mastalerz, Walter L Johnson, Guifen Zhang, Louis J Lombardo, Michael A Poss, George L Trainor, John S Tokarski, Matthew V Lorenzi, Dan You, Marco M Gottardis, Kathy F Baldwin, Jonathan Lippy, David S Nirschl, Ruhui Qiu, Arthur V Miller, Javed Khan, John S Sack, Ashok V Purandare.   

Abstract

SAR studies of pyrrolo[1,2-f]triazines as JAK2 inhibitors is presented. Achieving JAK2 inhibition selectively over JAK3 is discussed.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21282055     DOI: 10.1016/j.bmcl.2011.01.022

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

1.  Molecular dynamics and integrated pharmacophore-based identification of dual [Formula: see text] inhibitors.

Authors:  Maninder Kaur; Pankaj Kumar Singh; Manjinder Singh; Renu Bahadur; Om Silakari
Journal:  Mol Divers       Date:  2017-11-14       Impact factor: 2.943

2.  Dual inhibitors of Janus kinase 2 and 3 (JAK2/3): designing by pharmacophore- and docking-based virtual screening approach.

Authors:  Haneesh Jasuja; Navriti Chadha; Maninder Kaur; Om Silakari
Journal:  Mol Divers       Date:  2014-01-11       Impact factor: 2.943

3.  Targeted kinase selectivity from kinase profiling data.

Authors:  Francesca Milletti; Johannes C Hermann
Journal:  ACS Med Chem Lett       Date:  2012-03-14       Impact factor: 4.345

4.  Identification of Potent and Selective JAK1 Lead Compounds Through Ligand-Based Drug Design Approaches.

Authors:  Sathya Babu; Santhosh Kumar Nagarajan; Sruthy Sathish; Vir Singh Negi; Honglae Sohn; Thirumurthy Madhavan
Journal:  Front Pharmacol       Date:  2022-04-21       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.